PMID- 28677510
OWN - NLM
STAT- MEDLINE
DCOM- 20190204
LR  - 20190215
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 16
IP  - 4
DP  - 2018
TI  - The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus 
      Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
PG  - 368-375
LID - 10.2174/1570161115666170705153815 [doi]
AB  - BACKGROUND: Dyslipidaemia is a risk factor for macrovascular complications in 
      patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of 
      lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. 
      METHOD: A multicentre, non-interventional survey conducted in 6 Middle Eastern 
      countries (Bahrain, Oman, Qatar, United Arab Emirates, Kingdom of Saudi Arabia 
      and Kuwait). Patients with T2DM (n = 3338) taking LLD treatment for >/=3 months 
      with no dose change for >/=6 weeks were enrolled. RESULTS: The mean age (SD) of 
      T2DM patients was 56.6 +/-10.6 years; the majority (99%) were on statin 
      monotherapy. Only 48% of these patients achieved their low density lipoprotein 
      cholesterol (LDL-C) goal and 67.7% of the patients had a high cardiovascular 
      disease (CVD) risk according to the National Cholesterol Education Program (NCEP) 
      Adult Treatment Panel (ATP) III guidelines. Of those who achieved LDL-C goals 
      (n=1589), approximately one-third were at very high CVD risk and the patients who 
      had received statin monotherapy showed the highest proportion in LDL-C goal 
      attainment, followed by those treated with fibrate monotherapy. In a multivariate 
      logistic regression model, taking drugs daily (odds ratio, OR: 1.64, 95% CI 1.25, 
      2.15) and older age (OR: 1.09, 95% CI 1.01, 1.18) were significantly associated 
      with better odds of attaining LDL-C target. In contrast, patients with higher 
      levels of ApoA1 (OR: 0.73, 95% CI [0.67,0.79]), Metabolic Syndrome (OR: 0.64, 95% 
      CI [0.53, 0.76]), higher CV risk (OR: 0.33, 95% CI 0.27, 0.41), those who forgot 
      to take their medication (OR: 0.74, 95% CI 0.62,0.88) and those who stopped 
      taking medication when cholesterol became normal (OR: 0.67, 95% CI 0.55,0.82) 
      were significantly associated with lower odds of attaining LDL-C target. 
      CONCLUSION: The results of this study highlight the suboptimal management of 
      dyslipidaemia in T2DM patients at high and very high risk of CVD.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Shehab, Abdullah
AU  - Shehab A
AD  - Department of Internal Medicine, College of Medicine and Health Sciences, UAE 
      University, Al Ain, United Arab Emirates.
FAU - Al-Rasadi, Khalid
AU  - Al-Rasadi K
AD  - Sultan Qaboos University Hospital, Muscat, Oman.
FAU - Arafah, Mohamed
AU  - Arafah M
AD  - King Khalid University Hospital, Riyadh, Saudi Arabia.
FAU - Al-Hinai, Ali T
AU  - Al-Hinai AT
AD  - Sultan Qaboos University, College of Medicine & Health Sciences, Muscat, Oman.
FAU - Al Mahmeed, Wael
AU  - Al Mahmeed W
AD  - Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
FAU - Bhagavathula, Akshaya Srikanth
AU  - Bhagavathula AS
AD  - University of Gondar-College of Medicine and Health Sciences, Gondar, Ethiopia.
FAU - Al Tamimi, Omer
AU  - Al Tamimi O
AD  - Hamad Medical Corporation, Doha, Qatar.
FAU - Al Herz, Shorook
AU  - Al Herz S
AD  - King Fahad National Guard Hospital, Riyadh, Saudi Arabia.
FAU - Al Anazi, Faisal
AU  - Al Anazi F
AD  - Ministry of Health, Riyadh, Saudi Arabia.
FAU - Al Nemer, Khalid
AU  - Al Nemer K
AD  - Security Force Hospital, Riyadh, Saudi Arabia.
FAU - Metwally, Othman
AU  - Metwally O
AD  - King Fahad General Hospital, Jeddah, Saudi Arabia.
FAU - Alkhadra, Akram
AU  - Alkhadra A
AD  - King Fahad Hospital of the University, Khobar, Saudi Arabia.
FAU - Fakhry, Mohammed
AU  - Fakhry M
AD  - Soliman Fakieh Hospital, Jeddah, Saudi Arabia.
FAU - Elghetany, Hossam
AU  - Elghetany H
AD  - Soliman Fakieh Hospital, Jeddah, Saudi Arabia.
FAU - Medani, Abdel Razak
AU  - Medani AR
AD  - Dubai Hospital, Dubai, United Arab Emirates.
FAU - Yusufali, Afzal Hussein
AU  - Yusufali AH
AD  - American Hospital, Dubai, United Arab Emirates.
FAU - Al Jassim, Obaid
AU  - Al Jassim O
AD  - Dubai Hospital, Dubai, United Arab Emirates.
FAU - Al Hallaq, Omar
AU  - Al Hallaq O
AD  - American Hospital, Dubai, United Arab Emirates.
FAU - Baslaib, Fahad Omar Ahmed S
AU  - Baslaib FOAS
AD  - Rashid Hospital, Dubai, United Arab Emirates.
FAU - Alawadhi, Mahmoud
AU  - Alawadhi M
AD  - Al Amiri Hospital, Kuwait City, Kuwait.
FAU - Amin, Haitham
AU  - Amin H
AD  - Bahrain Defense Force Hospital, Riffa, Bahrain.
FAU - Al-Hashmi, Khamis
AU  - Al-Hashmi K
AD  - King Khalid University Hospital, Riyadh, Saudi Arabia.
FAU - Oulhaj, Abderrahim
AU  - Oulhaj A
AD  - Institute of Public Health, College of Medicine and Health Sciences, UAE 
      University, Al Ain, United Arab Emirates.
LA  - eng
SI  - ClinicalTrials.gov/NCT01031277
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hypolipidemic Agents)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/blood/diagnosis/epidemiology/*prevention & control
MH  - Cholesterol, LDL/*blood
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*epidemiology
MH  - Dyslipidemias/blood/diagnosis/*drug therapy/epidemiology
MH  - Female
MH  - Health Care Surveys
MH  - Humans
MH  - Hypolipidemic Agents/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Middle East/epidemiology
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Centralized pan-middle east survey (CEPHEUS)
OT  - cardiovascular disease (CVD)
OT  - dyslipidaemia
OT  - lipid-lowering drugs (LLDs)
OT  - low-density lipoprotein cholesterol (LDL-C)
OT  - middle east
OT  - type 2 diabetes mellitus (T2DM).
EDAT- 2017/07/06 06:00
MHDA- 2019/02/05 06:00
CRDT- 2017/07/06 06:00
PHST- 2017/04/24 00:00 [received]
PHST- 2017/05/20 00:00 [revised]
PHST- 2017/05/22 00:00 [accepted]
PHST- 2017/07/06 06:00 [pubmed]
PHST- 2019/02/05 06:00 [medline]
PHST- 2017/07/06 06:00 [entrez]
AID - CVP-EPUB-84531 [pii]
AID - 10.2174/1570161115666170705153815 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2018;16(4):368-375. doi: 10.2174/1570161115666170705153815.